Constitutive overexpression of pigment epithelium-derived factor inhibition of ocular melanoma growth and metastasis

Investigative Ophthalmology and Visual Science

Volumn 51, Issue 1, 2010, Pages 28-34

  Yang, Hua ^a   Grossniklaus, Hans E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LENTIVIRUS VECTOR; PIGMENT EPITHELIUM DERIVED FACTOR; EYE PROTEIN; MESSENGER RNA; NERVE GROWTH FACTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GENE THERAPY; CANCER GROWTH; CANCER INHIBITION; CELL MIGRATION; CONTROLLED STUDY; EYE CANCER; EYE MELANOMA; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER METASTASIS; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; MICROMETASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TUMOR VASCULARIZATION; TUMOR VOLUME; UVEA MELANOMA; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; ANIMAL; C57BL MOUSE; EXPERIMENTAL MELANOMA; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENE THERAPY; GENE VECTOR; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; GENETICS; LENTIVIRINAE; LIVER TUMOR; METABOLISM; METASTASIS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSGENIC MOUSE; TUMOR CELL CULTURE; UVEA TUMOR; VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; EYE PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE THERAPY; GENETIC VECTORS; HUMANS; LENTIVIRUS; LIVER NEOPLASMS; MELANOMA; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NEOVASCULARIZATION, PATHOLOGIC; NERVE GROWTH FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SERPINS; TRANSDUCTION, GENETIC; TRANSFECTION; TUMOR CELLS, CULTURED; UVEAL NEOPLASMS;

EID: 75749111061     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.09-4138     Document Type: Article

References (49)

1. Singh AD, Bergman L, Seregard S. Uveal melanoma: epidemiologic aspects. Ophthalmol Clin North Am. 2005;18:75-84.
2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110:956-961.
3. Tombran-Tink J, Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci. 1980;30:1700-1707.
4. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J. Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A. 1992;90:1526-1530.
5. Tombran-Tink J, Pawar H, Swaroop A, Rodriguez I, Chader GJ. Localization of the gene for pigment epithelium-derived factor (PEDF) to chromosome 17p13.1 and expression in cultured human retinoblastoma cells. Genomics. 1994;19:266-272.
6. Dawson DW, Volpert OV, Gillis P, et al. Pigment epitheliumderived factor: a potent inhibitor of angiogenesis. Science. 1999; 285:245-248.
7. Sawant S, Aparicio S, Tink AR, Lara N, Barnstable CJ, Tombran-Tink J. Regulation of factors controlling angiogenesis in liver development: a role for PEDF in the formation and maintenance of normal vasculature. Biochem Biophys Res Commun. 2004;325: 408-413.
8. Quan GM, Ojaimi J, Li Y, Kartsogiannis V, Zhou H, Choong PF. Localization of pigment epithelium-derived factor in growing mouse bone. Calcif Tissue Int. 2005;76:146-153.
9. Bilak MM, Corse AM, Bilak SR, Lehar M, Tombran-Tink J, Kuncl RW. Pigment epithelium-derived factor (PEDF) protects motor neurons from chronic glutamate-mediated neurodegeneration. J Neuropathol Exp Neurol. 1999;58:719-728.
10. Kuncl RW, Bilak MM, Bilak SR, Corse AM, Royal W, Becerra SP. Pigment epithelium-derived factor is elevated in CSF of patients with amyotrophic lateral sclerosis. J Neurochem. 2002;81:178-184.
11. Tombran-Tink J, Mazuruk K, Rodriguez IR, et al. Organization, evolutionary conservation, expression and unusual Alu density of the human gene for pigment epithelium-derived factor, a unique neurotrophic serpin. Mol Vis. 1996;2:11.
12. Yang H, Xu Z, Iuvone PM, Grossniklaus HE. Angiostatin decreases cell migration and vascular endothelium growth factor (VEGF) and pigment epithelium derived factor (PEDF) RNA ratio in vitro and in a murine ocular melanoma model. Mol Vis. 2006;22:511-517.
13. Ortego J, Escribano J, Becerra SP, Coca-Prados M. Gene expression of the neurotrophic pigment epithelium-derived factor in the human ciliary epithelium: synthesis and secretion into the aqueous humor. Invest Ophthalmol Vis Sci. 1996;37:2759-2767.
14. Behling KC, Surace EM, Bennett J. Pigment epithelium-derived factor expression in the developing mouse eye. Mol Vis. 2002;18: 449-454.
15. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol. 2001;188:253-263.
16. Raisler BJ, Berns KI, Grant MB, et al. Adeno-associated virus type-2 expression of pigmented epithelium-derived factor or Kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci U S A. 2002;99:8909-8914.
17. Tsao YP, Ho TC, Chen SL, Cheng HC. Pigment epithelium-derived factor inhibits oxidative stress-induced cell death by activation of extracellular signal-regulated kinases in cultured retinal pigment epithelial cells. Life Sci. 2006;79:545-550.
18. Yamagishi S, Matsui T, Nakamura K, et al. Pigment-epitheliumderived factor suppresses expression of receptor for advanced glycation end products in the eye of diabetic rats. Ophthalmic Res. 2007;39:92-97.
19. Cai J, Parr C, Watkins G, Jiang WG, Boulton M. Decreased pigment epithelium-derived factor expression in human breast cancer progression. Clin Cancer Res. 2006;12:3510-3517.
20. Doll JA, Stellmach VM, Bouck NP, et al. Pigment epitheliumderived factor regulates the vasculature and mass of the prostate and pancreas. Nat Med. 2003;9:774-780.
21. Uehara H, Miyamoto M, Kato K, et al. Expression of pigment epithelium-derived factor decreases liver metastasis and correlates with favorable prognosis for patients with ductal pancreatic adenocarcinoma. Cancer Res. 2004;64:3533-3537.
22. Halin S, Wikstrom P, Rudolfsson SH, et al. Decreased pigment epithelium-derived factor is associated with metastatic phenotype in human and rat prostate tumors. Cancer Res. 2004;64:5664-5671.
23. Crawford SE, Stellmach V, Ranalli M, et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci. 2001;114:4421-4428.
24. Guan M, Yam HF, Su B, et al. Loss of pigment epithelium derived factor expression in glioma progression. J Clin Pathol. 2003;56: 277-282.
25. Guan M, Pang CP, Yam HF, et al. Inhibition of glioma invasion by overexpression of pigment epithelium-derived factor. Cancer Gene Ther. 2004;11:325-332.
26. Garcia M, Fernandez-Garcia NI, Rivas V, et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res. 2004;64:5632-5642.
27. Browne M, Stellmach V, Cornwell M, et al. Gene transfer of pigment epithelium-derived factor suppresses tumor growth and angiogenesis in a hepatoblastoma xenograft model. Pediatr Res. 2006;60:282-287.
28. Takenaka K, Yamagishi S, Jinnouchi Y, et al. Pigment epitheliumderived factor (PEDF)-induced apoptosis and inhibition of vascular endothelial growth factor (VEGF) expression in MG63 human osteosarcoma cells. Life Sci. 2005;77:3231-3241.
29. Ek ET, Dass CR, Contreras KG, Choong PF. Pigment epitheliumderived factor overexpression inhibits orthotopic osteosarcoma growth, angiogenesis and metastasis. Cancer Gene Ther. 2007;14: 616-626.
30. Abe R, Shimizu T, Yamagishi S, et al. Overexpression of pigment epithelium-derived factor decreases angiogenesis and inhibits the growth of human malignant melanoma cells in vivo. Am J Pathol. 2004;164:1225-1232.
31. Garcia M, Fernandez-Garcia NI, Rivas V, et al. Inhibition of xenografted human melanoma growth and prevention of metastasis development by dual antiangiogenic/antitumor activities of pigment epithelium-derived factor. Cancer Res. 2004;64:5632-5642.
32. Dithmar S, Rusciano D, Grossniklaus HE. A new technique for implantation of tissue culture melanoma cells in a murine model of metastatic ocular melanoma. Melanoma Res. 2000;10:2-8.
33. Dithmar S, Grossniklaus HE, Albert DM. Animal models of uveal melanoma. Melanoma Res. 2000;10:195-211.
34. Yang H, Fang G, Huang X, et al. In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases. Melanoma Res. 2008;18:95-103.
35. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:2002-2007.
36. Tombran-Tink J, Johnson LV. Neuronal differentiation of retinoblastoma cells induced by medium conditioned by human RPE cells. Invest Ophthalmol Vis Sci. 1989;30:1700-1707.
37. Fernandez-Garcia NI, Volpert OV, Jimenez B. Pigment epitheliumderived factor as a multifunctional antitumor factor. J Mol Med. 2007;85:15-22.
38. Gimbrone MA Jr, Leapman SB, Cotran RS, et al. Tumor dormancy in vivo by prevention of neovascularization. J Exp Med. 1972;136: 261-276.
39. Brem S, Brem H, Folkman J, et al. Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res. 1976;36:2807-2812.
40. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med. 1995;1:149-153.
41. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
42. Arbiser JL, Moses MA, Fernandez CA, et al. Oncogenic H-ras stimulates tumor angiogenesis by two distinct pathways. Proc Natl Acad Sci USA. 1997;94:861-866.
43. Folkman J. Incipient angiogenesis. J Natl Cancer Inst. 2000;92: 94-95.
44. Folkman J. Angiogensis Annu Rev Med. 2006;57:1-18.
45. Watnick RS, Cheng Y-N, Rangarajan A, et al. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 2003;3:219-231.
46. Connell RD. Patent focus on cancer chemotherapeutics, V: angiogenesis agents: September 2001-August 2002. Exp Opin Ther Patents. 2002;12:1763-1782.
47. Mousa SA. Mechanisms of angiogenesis in vascular disorders: potential therapeutic targets. Drugs Fut. 1998;23:51.
48. Paper DH. Natural products as angiogenesis inhibitors. Planta Med. 1998;64:686-695.
49. Velazquez OC, Herlyn M. The vascular phenotype of melanoma metastasis. Clin Exp Metast. 2003;20:229-235.